$CLOV Income Statement | Understand Stock

$CLOV

$4.63 +$0.07 (1.54%) Close

$CLOV Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of operations and comprehensive loss

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenues:
Premiums earned, net (Net of ceded premiums of $375, $399, and $444 for the year ended December 31, 2025, 2024, and 2023, respectively.)
Medicate Advantage
Total premiums earned, net (Net of ceded premiums of $375, $399, and $444 for the year ended December 31, 2025, 2024, and 2023, respectively.)

Non-Insurance revenue
Direct Contracting
Total non-Insurance revenue

Other income
Total revenues
Operating expenses:
Net medical claims incurred
Medicate Advantage
Direct Contracting
Total net medical claims incurred

Other medical costs
Salaries and benefits
General and administrative expenses
Premium deficiency reserve (benefit) expense
Impairment of goodwill and other intangible assets
Premium deficiency reserve benefit
Depreciation and amortization
Restructuring costs
Other expense
Total operating expenses

Loss from continuing operations
Change in fair value of warrants
Interest expense
Amortization of notes and securities discounts
Gain on derivative
Loss on investment
Gain (Loss) on Extinguishment of Debt
Net loss from continuing operations
Net income (loss) from discontinued operations
Net loss
Per share data:
Net loss per share attributable to Class A and Class B common stockholders - basic (in dollars per share)
Basic weighted average number of class A and class B common shares and common share equivalents outstanding (in shares)
Diluted weighted average number of class A and class B common shares and common share equivalents outstanding (in shares)
Unrealized (loss) gain on available-for-sale investments
Continuing operations:
Basic loss per share (in dollars per share)
Diluted loss per share (in dollars per share)
Discontinued operations:
Basic earnings (loss) per share (in dollars per share)
Diluted earnings (loss) per share (in dollars per share)

Net unrealized gain on available-for-sale investments
Comprehensive loss

Comments